Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings

AIDS

Volumn 24, Issue 12, 2010, Pages 1887-1895

  Athan, Eugene ^a,b   O'Brien, Daniel P ^a   Legood, Rosa ^b  

^a Department of Infectious Diseases Barwon Health ^*  (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

AIDS; Cost effectiveness; HIV; Low cost CD4 T cell count; Quality of life

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STAGING; WORLD HEALTH ORGANIZATION;

AFRICA SOUTH OF THE SAHARA; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MARKOV CHAINS; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS;

EID: 77954757099     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833b25ed     Document Type: Article

References (55)

1. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination anti-retroviral therapy for HIV disease. New Engl J Med 2001; 344:824-831. (Pubitemid 32222162)
2. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, et al. The cost effectiveness of highly active anti-retroviral therapy, Canada 1991-2001. AIDS 2004; 18:2411-2418.
3. Vijayaraghavan A,Efrusy MB, Mazonson PD, EbrahimO, Sanne IM, Santas CS. Cost effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. AIDS 2007; 46:91-100.
4. Stringer JSA, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale up of antiretroviral therapy at primary care sites in Zambia. JAMA 2006; 296:782-793.
5. Cleary SM, McIntyre D, Boulle AM. The cost effectiveness of antiretroviral treatment in Khayelitsha, South Africa: a primary data analysis. Cost Eff Resour Alloc 2006; 4:20.
6. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost effectiveness of HIV treatment in resource poor settings: the case of Cote d'Ivoire. New Engl J Med 2006; 355:1141-1153.
7. Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, Platt RW, et al. Cost effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2006; 3:e4.
8. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224.
9. Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis 2005; 41:376-385.
10. Proposed WHO staging system for HIV infection and disease: preliminary testing by an international collaborative cross sectional study. AIDS 1993; 7:711-718.
11. Gallant JE, Somani J, Chaisson RE, Stanton D, Smith M, Quinn TC. Diagnostic accuracy of three clinical case definitions for advanced HIV disease. AIDS 1992; 6:295-299
12. WHO. Case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV related disease in adults and children. Geneva: WHO; 2006.
13. WHO. Antiretroviral therapy for HIV infection in adults and adolescents; November 2009. http://www.who.int/hiv/pub/arv/advice/en/.
14. McGrath N, Kranzer K, Saul J, Crampin AC, Malema S, Kachi-wanda L, et al. Estimating the need for antiretroviral treatment and an assessment of a simplified HIV/AIDS case definition in rural Malawi. AIDS 2007; 21 (Suppl 6):S105-S113.
15. Kagaayi J, Makumbi F, Nakigozi G, Wawer MJ, Gray RH, Serwadda D, Reynolds SJ. WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda. AIDS 2007; 21:1208-1210.
16. Callens SFJ, Kitetele F, Lusiama J, Shabani N, Edidi S, Colebun-ders R, et al. Computed CD4 percentage as a low cost method for determining pediatric antiretroviral treatment eligibility. BMC Infect Dis 2008; 8:31.
17. MacLennan CA, Liu MKP, White SA, Van Oosterhout JJG, Simukonda F, Bwanali J, et al. Diagnostic accuracy and clinical utility of a simplified low cost method of counting CD4 cells with flow cytometry in Malawi: diagnostic accuracy study. BMJ 2007; 335:190-194.
18. Pattanapanyasat K, Phuang-Ngern Y, Lerdwana S, Wasinrapee P, Sakulploy N, Noulsri E, et al. Evaluation of a single platform microcapillary flow cytometer for enumeration of absolute CD4R T lymphocyte counts in HIV-1 infected Thai patients. Cytometry B Clin Cytom 2007; 72B:387-396.
19. Janossy G, Jani IV, Bradley NJ, Bikoue A, Pitfield T, Glencross DK. Affordable CD4R T cell counting by flow cytometry: CD45 gating for volumetric analysis. Clin and Diag Lab Immun 2002; 9:1085-1094.
20. Dieye TN, Vereecken C, Diallo AA, Ondoa P, Diaw PA, Camara M, et al. Absolute CD4 T cell counting in resource poor settings. Direct volumetric measurements versus bead based clinical flow cytometry instruments. AIDS 2005; 39:32-37.
21. Balakrishnan P, Dunne M, Kumarasamy N, Crowe S, Subbu-lakshmi G, Ganesh AK, et al. An inexpensive, simple, and manual method of CD4 T cell quantitation in HIV infected individuals for use in developing countries. AIDS 2004; 36:1006-1010.
22. Bacchetti P, Moss AR. Incubation period of AIDS in San Francisco. Nature 1989; 338:251-253.
23. Rutherford GW, Lifson AR, Hessol NA, Darrow WW, O'Malley PM, Buchbinder SP, et al. Course of HIV-1 infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ 1990; 301:1183-1188.
24. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
25. Phillips A, Pezzotti P, CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
26. Bachetti P, Osmand D, Chaisson RE, Dritz S, Rutherford GW, Swig L, Moss AR. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis 1988; 157:1044-1047.
27. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B. Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. New Engl J Med 1987; 317:1297-1302.
28. Osmond D, Harlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994; 271:1083-1087.
29. Saravolatz L, Neaton J, Sacks L, Deyton L, Rhame F, Sherer R. CD4R lymphocyte counts and patterns of mortality among patients infected with human immunodeficiency virus who were enrolled in community programs for clinical research on AIDS. Clin Infect Dis 1996; 11:513-520.
30. Badri M, Lawn SD, Wood R. Short term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: alongitudinal study. Lancet 2006; 368:1254-1259.
31. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an anti-retroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776.
32. Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R. When to initiate highly active antiretroviral therapy in sub Saharan Africa? A South African cost effectiveness study. Antivir Ther 2006; 11:63-72.
33. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. New Engl J Med 1997; 337:725-733.
34. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomised, double blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial: Italy, the Netherlands, Canada and Australia study. JAMA 1998; 279:930-937.
35. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-87.
36. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamuvidine, efavirenz plus indinavir, and indinavir plus zidovudine and lamuvidine in the treatment of HIV-1 infection in adults. New Engl J Med 1999; 341:1865-1873.
37. Diomande FVK, Bissagnene E, Nkengasongn JN, Maurice C, Monga B, Laga M, Nolan ML. The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: empirical data from Cote d'Ivoire's drug access initiative. AIDS 2003; 17:S87-S93.
38. Collazos J, Knobel H, Casado JL, On behalf of the Grupo Espanol para el Estudio Multifactorial de la Adherencia (GEE-MA). CD4 count and viral load time courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system. HIV Med 2006; 7:504-513
39. Untangling the web of price reductions: a pricing guide for ARVs in developing countries. 12th ed. Geneva: Medicins sans Fron-tieres; 2009. [Accessed 10 June 2009].
40. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost effectiveness in health and medicine. New York: Oxford University Press; 1996.
41. Brazier J, Roberts J, Deverill M. The estimation of a preference based measure of health from the SF-36. J Health Econ 2002; 21:271-292.
42. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference based single index from the UK SF-36 health survey. J Clin Epidemiol 1998; 51:1115-1128.
43. Jelsma J, Maclean E, Hughes J, Tinise X, Darder M. An investigation into the health related quality of life of individuals living with HIV who are receiving HAART. AIDS Care 2005; 17:579-588.
44. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. York: Centre for Health Economics, York Health Economics Consortium, NHS Centre for Reviews & Dissemination; 1995.
45. O'Keefe EA, Wood R. The impact of human immunodeficiency virus (HIV) infection on quality of life in a multiracial South African population. Qual Life Res 1996; 5:275-280.
46. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22:27-38
47. WHO. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organisation; 2002.
48. Garber AM. Advances in cost effectiveness analysis of health interventions. In: Culer AJ, Newhouse JP, editors. Handbook of health economics. Vol 1A. Amsterdam: Elsevier; 2000. pp. 181-221
49. GDP-first quarter 2007. Statistics South Africa; 2007:1-42. http://www.indexmundi.com/g/r.aspx?c=mr&v=67. [Accessed July 2008]
50. GDP Cote d'Ivoire 2007. Statistics Cote d'Ivoire; 2007. http://www.indexmundi.com/g/r.aspx?c=mramp;v=67. [Accessed July 2008].
51. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins sans Frontieres. AIDS 2008; 22:1305-1312.
52. Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV anti-retroviral treatment: early versus later. AIDS 2005; 39:562-569.
53. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV infected adults in west Africa. AIDS 2007; 21:2483-2491.
54. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al., the Antiretroviral Therapy in Lower Income Countries Collaboration; ART Cohort Collaboration groups. Mortality of HIV-1 infected patients in the first year of anti-retroviral therapy: comparison between low income and high income countries. Lancet 2006; 367:817-824.
55. Madhivanan P, Krupp K. Technological challenges in diagnosis and management of HIV infection in resource limited settings. BMJ 2007; 335:165-166.